TACR1 and pancreatic neoplasm: By contrary, SP analogue antagonists (synonymous of the NK-1 receptor antagonists) inhibit tumor growth in pancreatic cancer via a dual mechanism that involves both antiproliferative and antiangiogenic properties [41].